25 June 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Medicines (Xetra: 938858 - news) and Healthcare products Regulatory Agency (MHRA) inspection

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that the inspection in early June of our Cramlington site, by the MHRA, was completed successfully. The inspector spent three days at our facility and raised no critical or major observations. Critical and/or major observations is the terminology used by the inspector to define shortcomings that usually require remedial action before a license can be granted. The first inspection of what is effectively a new facility is the most challenging and it is a credit to the Angel team that Cramlington met the standard required to be added to Angel's GMP (KOSDAQ: 018290.KQ - news) license.

Dr Paul Harper, ABH Chairman said: "This is a significant achievement for the company and opens the way to expand our business by being able to offer GMP capacity suitable to accommodate larger programmes. This has been achieved whilst maintaining our existing business activities and undertaking the integration of Angel Biomedical Ltd as a new Group company. The Board of Directors wish to commend the team for an exemplary performance."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

Read more:
Angel Biotechnology - Successful Completion of MHRA Inspection